

Cathy Davies

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8622910/publications.pdf>

Version: 2024-02-01

39
papers

2,274
citations

394421

19
h-index

414414

32
g-index

41
all docs

41
docs citations

41
times ranked

2887
citing authors

#	ARTICLE	IF	CITATIONS
1	What causes psychosis? An umbrella review of risk and protective factors. <i>World Psychiatry</i> , 2018, 17, 49-66.	10.4	387
2	Transdiagnostic psychiatry: a systematic review. <i>World Psychiatry</i> , 2019, 18, 192-207.	10.4	218
3	Development and Validation of a Clinically Based Risk Calculator for the Transdiagnostic Prediction of Psychosis. <i>JAMA Psychiatry</i> , 2017, 74, 493.	11.0	206
4	Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis. <i>World Psychiatry</i> , 2018, 17, 196-209.	10.4	183
5	Prenatal and perinatal risk and protective factors for psychosis: a systematic review and meta-analysis. <i>Lancet Psychiatry</i> , 2020, 7, 399-410.	7.4	182
6	Cannabis-associated psychosis: Neural substrate and clinical impact. <i>Neuropharmacology</i> , 2017, 124, 89-104.	4.1	140
7	Long-term validity of the At Risk Mental State (ARMS) for predicting psychotic and non-psychotic mental disorders. <i>European Psychiatry</i> , 2017, 42, 49-54.	0.2	104
8	What Causes the Onset of Psychosis in Individuals at Clinical High Risk? A Meta-analysis of Risk and Protective Factors. <i>Schizophrenia Bulletin</i> , 2020, 46, 110-120.	4.3	103
9	Can We Reduce the Duration of Untreated Psychosis? A Systematic Review and Meta-Analysis of Controlled Interventional Studies. <i>Schizophrenia Bulletin</i> , 2018, 44, 1362-1372.	4.3	100
10	Efficacy and Acceptability of Interventions for Attenuated Positive Psychotic Symptoms in Individuals at Clinical High Risk of Psychosis: A Network Meta-Analysis. <i>Frontiers in Psychiatry</i> , 2018, 9, 187.	2.6	87
11	Transdiagnostic Risk Calculator for the Automatic Detection of Individuals at Risk and the Prediction of Psychosis: Second Replication in an Independent National Health Service Trust. <i>Schizophrenia Bulletin</i> , 2019, 45, 562-570.	4.3	74
12	Cannabidiol as a potential treatment for psychosis. <i>Therapeutic Advances in Psychopharmacology</i> , 2019, 9, 204512531988191.	2.7	74
13	Preventive Treatments for Psychosis: Umbrella Review (Just the Evidence). <i>Frontiers in Psychiatry</i> , 2019, 10, 764.	2.6	72
14	Why transition risk to psychosis is not declining at the OASIS ultra high risk service: The hidden role of stable pretest risk enrichment. <i>Schizophrenia Research</i> , 2018, 192, 385-390.	2.0	45
15	Unmet needs in patients with brief psychotic disorders: Too ill for clinical high risk services and not ill enough for first episode services. <i>European Psychiatry</i> , 2019, 57, 26-32.	0.2	34
16	Long term outcomes of acute and transient psychotic disorders: The missed opportunity of preventive interventions. <i>European Psychiatry</i> , 2018, 52, 126-133.	0.2	32
17	GABA, Glutamate and Neural Activity: A Systematic Review With Meta-Analysis of Multimodal 1H-MRS-fMRI Studies. <i>Frontiers in Psychiatry</i> , 2021, 12, 644315.	2.6	30
18	Diagnostic and Prognostic Significance of DSM-5 Attenuated Psychosis Syndrome in Services for Individuals at Ultra High Risk for Psychosis. <i>Schizophrenia Bulletin</i> , 2018, 44, 264-275.	4.3	26

#	ARTICLE	IF	CITATIONS
19	Oxytocin modulates hippocampal perfusion in people at clinical high risk for psychosis. <i>Neuropsychopharmacology</i> , 2019, 44, 1300-1309.	5.4	26
20	A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis. <i>Translational Psychiatry</i> , 2020, 10, 311.	4.8	23
21	The Yin and Yang of Cannabis: A Systematic Review of Human Neuroimaging Evidence of the Differential Effects of δ^9 -Tetrahydrocannabinol and Cannabidiol. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2021, 6, 636-645.	1.5	18
22	A Case of a College Student Presenting With Mild Mental Health Problems. <i>JAMA Psychiatry</i> , 2018, 75, 1298.	11.0	17
23	Transdiagnostic Individualized Clinically Based Risk Calculator for the Detection of Individuals at Risk and the Prediction of Psychosis: Model Refinement Including Nonlinear Effects of Age. <i>Frontiers in Psychiatry</i> , 2019, 10, 313.	2.6	16
24	Intranasal oxytocin increases heart-rate variability in men at clinical high risk for psychosis: a proof-of-concept study. <i>Translational Psychiatry</i> , 2020, 10, 227.	4.8	16
25	Evaluation of variability in individual response to treatments in the clinical high-risk state for psychosis: A meta-analysis. <i>Schizophrenia Research</i> , 2021, 227, 20-27.	2.0	11
26	Altered relationship between cortisol response to social stress and mediotemporal function during fear processing in people at clinical high risk for psychosis: a preliminary report. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 461-475.	3.2	11
27	Acute oxytocin effects in inferring others' beliefs and social emotions in people at clinical high risk for psychosis. <i>Translational Psychiatry</i> , 2020, 10, 203.	4.8	10
28	Neurochemical effects of oxytocin in people at clinical high risk for psychosis. <i>European Neuropsychopharmacology</i> , 2019, 29, 601-615.	0.7	8
29	Transition to psychosis in randomized clinical trials of individuals at clinical high risk of psychosis compared to observational cohorts: a systematic review and meta-analysis. <i>European Psychiatry</i> , 2021, 64, e51.	0.2	7
30	Methodological Biases in CBT Trial – Commentary: Modular Cognitive-Behavioral Therapy for Affective Symptoms in Young Individuals at Ultra-High Risk of First Episode of Psychosis: Randomized Controlled Trial. <i>Frontiers in Psychiatry</i> , 2020, 11, 394.	2.6	6
31	GABAA and NMDA receptor density alterations and their behavioral correlates in the gestational methylazoxymethanol acetate model for schizophrenia. <i>Neuropsychopharmacology</i> , 2022, 47, 687-695.	5.4	6
32	OUP accepted manuscript. <i>Schizophrenia Bulletin</i> , 2021, , .	4.3	2
33	34.2 IMPROVING THE DETECTION OF INDIVIDUALS AT RISK OF PSYCHOSIS IN SECONDARY MENTAL HEALTH CARE. <i>Schizophrenia Bulletin</i> , 2018, 44, S56-S57.	4.3	0
34	T122. UNMET NEEDS IN PATIENTS WITH ACUTE TRANSIENT PSYCHOTIC DISORDERS (ATPD): ANALYSIS OF PATHWAYS TO CARE: AN 8 YEARS FOLLOW-UP STUDY. <i>Schizophrenia Bulletin</i> , 2018, 44, S162-S163.	4.3	0
35	F256. CAN WE REDUCE THE DURATION OF UNTREATED PSYCHOSIS?. <i>Schizophrenia Bulletin</i> , 2018, 44, S323-S323.	4.3	0
36	S149. EFFECTS OF INTRANASAL OXYTOCIN ON RESTING CEREBRAL BLOOD FLOW IN PEOPLE AT ULTRA-HIGH RISK FOR PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2018, 44, S383-S383.	4.3	0

#	ARTICLE	IF	CITATIONS
37	F94. EFFECTS OF OXYTOCIN ON NEUROCHEMICAL METABOLITES IN PSYCHOSIS RISK. Schizophrenia Bulletin, 2019, 45, S289-S290.	4.3	0
38	T139. OXYTOCIN ENHANCES NEURAL EFFICIENCY IN INFERRING OTHERS' SOCIAL EMOTIONS IN PEOPLE AT CLINICAL HIGH RISK FOR PSYCHOSIS. Schizophrenia Bulletin, 2020, 46, S283-S284.	4.3	0
39	T145. EFFECTS OF CANNABIDIOL ON EMOTION PROCESSING IN PSYCHOSIS RISK: AN FMRI INVESTIGATION. Schizophrenia Bulletin, 2020, 46, S286-S286.	4.3	0